Metabolic rewiring induced by ranolazine improves melanoma responses to targeted therapy and immunotherapy.
Redondo-Muñoz M, Rodriguez-Baena FJ, Aldaz P, Caballé-Mestres A, Moncho-Amor V, Otaegi-Ugartemendia M, Carrasco-Garcia E, Olias-Arjona A, Lasheras-Otero I, Santamaria E, Bocanegra A, Chocarro L, Grier A, Dzieciatkowska M M, Bigas C, Martin J, Urdiroz-Urricelqui U, Marzo F, Santamaria E, Kochan G, Escors D, Larrayoz IM, Heyn H, D'Alessandro A, Attolini CS, Matheu A, Wellbrock C, Benitah SA, Sanchez-Laorden B, Arozarena I.
Redondo-Muñoz M, et al. Among authors: d alessandro a.
Nat Metab. 2023 Sep;5(9):1544-1562. doi: 10.1038/s42255-023-00861-4. Epub 2023 Aug 10.
Nat Metab. 2023.
PMID: 37563469
Free PMC article.
Combination of RANO with anti-PD-L1 antibodies strongly improves survival by increasing antitumour immune responses. Altogether, we show that RANO increases the efficacy of targeted melanoma therapy through its effects on FAO and the methionine salvage pathway. ...
Combination of RANO with anti-PD-L1 antibodies strongly improves survival by increasing antitumour immune responses. Altogether, we s …